What is Roth Capital’s Forecast for CLRB FY2029 Earnings?
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for Cellectar Biosciences in a research report issued on Thursday, March 13th. Roth Capital analyst J. Aschoff expects that the biopharmaceutical company will post earnings per share of $0.21 for the year. The consensus […]
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for Cellectar Biosciences in a research report issued on Thursday, March 13th. Roth Capital analyst J. Aschoff expects that the biopharmaceutical company will post earnings per share of $0.21 for the year. The consensus […]
